Earnings Feed
Start Free
AbbVie Inc.·4

Feb 20, 6:35 PM ET

Donoghoe Nicholas 4

4 · AbbVie Inc. · Filed Feb 20, 2026

Research Summary

AI-generated summary of this filing

Updated

AbbVie (ABBV) EVP Nicholas Donoghoe Receives Performance Awards

What Happened

  • Nicholas Donoghoe, Executive Vice President and Chief Business & Strategy Officer of AbbVie (ABBV), was granted multiple performance-based equity awards reported on Feb 18, 2026. The filing shows acquisition of 13,031; 4,632; 5,172; and 6,222 shares (total 29,057) at $0, and a derivative award (stock option) covering 20,312 shares at $0. The performance restrictions were certified as met by the Compensation Committee; the shares will be issued to Donoghoe on February 28, 2026. The option is a standard employee stock option (see vesting schedule below).

Key Details

  • Transaction date reported: 2026-02-18; Form 4 filed: 2026-02-20 (appears timely).
  • Price reported: $0.00 for all items (typical for awards/grants).
  • Award breakdown: 13,031; 4,632; 5,172; 6,222 common shares (performance-vested awards) and a stock option covering 20,312 shares (derivative).
  • Option vesting: exercisable in annual increments of 6,771 on 2/18/2027, 6,771 on 2/18/2028, and 6,770 on 2/18/2029 (total 20,312) — grant per AbbVie’s 2013 Incentive Stock Program.
  • Footnotes: F1–F4 — performance-based restricted stock/share awards granted in 2023–2025 with vesting tied to EPS, relative TSR, or return on equity; restrictions were released upon certification. F5 — employee stock option granted under plan.
  • Shares owned after transaction: not provided in the excerpt of this filing.
  • No 10b5-1 plan, tax-withholding sale, or late-filing indicator noted in the provided data.

Context

  • These entries are awards/grants (transaction code A) rather than open-market purchases or sales; they reflect compensation and performance-based pay rather than a direct insider buy/sell signal.
  • The $0 acquisition amounts indicate issuance of awards (not a cash purchase). The option grant is not an exercise; it will vest over the next three years per the schedule above.

Insider Transaction Report

Form 4
Period: 2026-02-18
AbbVie Inc.ABBV
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
Transactions
  • Award

    Common Stock, $0.01 par value

    [F1]
    2026-02-18+13,031→ 71,278 total
  • Award

    Common Stock, $0.01 par value

    [F2]
    2026-02-18+4,632→ 75,910 total
  • Award

    Common Stock, $0.01 par value

    [F3]
    2026-02-18+5,172→ 81,082 total
  • Award

    Common Stock, $0.01 par value

    [F4]
    2026-02-18+6,222→ 87,304 total
  • Award

    Option (Right to buy)

    [F5]
    2026-02-18+20,312→ 20,312 total
    Exercise: $230.04Exp: 2036-02-17→ Common Stock (20,312 underlying)
Footnotes (5)
  • [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Nicholas J. Donoghoe|2026-02-20

Documents

1 file
  • 4
    form4-02202026_060205.xmlPrimary